Michael M Lederman
Overview
Explore the profile of Michael M Lederman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
292
Citations
15224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freeman M, Hossain M, Burrowes S, Jeudy J, Diaz-Mendez F, Mitchell S, et al.
Circ Cardiovasc Imaging
. 2024 Dec;
18(1):e017033.
PMID: 39641168
Background: Persistent immune activation is linked to elevated cardiovascular diseases in people with HIV on antiretroviral therapy. The fat attenuation index (FAI) is a measure of peri-coronary inflammation that independently...
2.
Panigrahi S, Mayne E, Louw S, Funderburg N, Chakraborty A, Jacobson J, et al.
iScience
. 2024 Oct;
27(10):110909.
PMID: 39391731
People with HIV (PWH) experience endothelial dysfunction (ED) that is aggravated by chronic inflammation and microbial translocation across a damaged gut barrier. Although this paradigm is well-described, downstream pathways that...
3.
Henrich T, Bosch R, Godfrey C, Mar H, Nair A, Keefer M, et al.
Cell Rep Med
. 2024 Sep;
5(10):101745.
PMID: 39321793
Key HIV cure strategies involve reversing immune dysfunction and limiting the proliferation of infected T cells. We evaluate the safety of sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in...
4.
Lederman M, Greenspan N
Pathog Immun
. 2024 Sep;
9(2):152-171.
PMID: 39315014
No abstract available.
5.
Cyktor J, Yeh E, Ribaudo H, Hoeth D, Naqvi A, Bell T, et al.
J Acquir Immune Defic Syndr
. 2024 Sep;
96(5):481-485.
PMID: 39287554
Background: People with HIV-1 often have chronic inflammation leading to severe non-AIDS morbidity and mortality. The AIDS Clinical Trials Group Study A5314 sought to lower inflammation with low-dose methotrexate (LDMTX)....
6.
Poveda E, Fitzgerald W, Alonso-Dominguez J, Aguayo-Arjona J, Marino A, Alvarez H, et al.
Front Immunol
. 2024 Sep;
15:1446730.
PMID: 39267749
Plasma cytokine levels were quantified among 30 persons with HIV (PWH) identified as elite controllers (15 transient controllers [studied a median of 1.38 years before losing viral control] and 15...
7.
Premeaux T, Bowler S, Friday C, Moser C, Hoenigl M, Lederman M, et al.
iScience
. 2024 May;
27(6):109945.
PMID: 38812553
Despite the success of antiretroviral therapy (ART), individuals with HIV remain at risk for experiencing non-AIDS adverse events (NAEs), including cardiovascular complications and malignancy. Several surrogate immune biomarkers in blood...
8.
9.
Harper J, Betts M, Lichterfeld M, Muller-Trutwin M, Margolis D, Bar K, et al.
Pathog Immun
. 2024 Mar;
8(2):179-222.
PMID: 38505662
[This corrects the article DOI: 10.20411/pai.v8i2.665.].
10.
Harper J, Betts M, Lichterfeld M, Muller-Trutwin M, Margolis D, Bar K, et al.
Pathog Immun
. 2024 Mar;
8(2):115-157.
PMID: 38455668
Once a death sentence, HIV is now considered a manageable chronic disease due to the development of antiretroviral therapy (ART) regimens with minimal toxicity and a high barrier for genetic...